ID   AOFA_RAT                Reviewed;         526 AA.
AC   P21396; Q63817;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   24-JUL-2024, entry version 158.
DE   RecName: Full=Amine oxidase [flavin-containing] A {ECO:0000305};
DE            EC=1.4.3.21 {ECO:0000269|PubMed:18391214, ECO:0000269|PubMed:20493079};
DE            EC=1.4.3.4 {ECO:0000269|PubMed:20493079};
DE   AltName: Full=Monoamine oxidase type A;
DE            Short=MAO-A;
GN   Name=Maoa {ECO:0000312|RGD:61898};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1368522; DOI=10.1271/bbb1961.54.253;
RA   Kuwahara T., Takamoto S., Ito A.;
RT   "Primary structure of rat monoamine oxidase A deduced from cDNA and its
RT   expression in rat tissues.";
RL   Agric. Biol. Chem. 54:253-257(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-526.
RC   TISSUE=Liver;
RX   PubMed=1526120; DOI=10.1016/0305-0491(92)90286-z;
RA   Kwan S.W., Abell C.W.;
RT   "cDNA cloning and sequencing of rat monoamine oxidase A: comparison with
RT   the human and bovine enzymes.";
RL   Comp. Biochem. Physiol. 102B:143-147(1992).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=20493079; DOI=10.1016/0197-0186(86)90182-8;
RA   O'Carroll A.M., Bardsley M.E., Tipton K.F.;
RT   "The oxidation of adrenaline and noradrenaline by the two forms of
RT   monoamine oxidase from human and rat brain.";
RL   Neurochem. Int. 8:493-500(1986).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF PHE-208.
RX   PubMed=9162023; DOI=10.1074/jbc.272.22.14033;
RA   Tsugeno Y., Ito A.;
RT   "A key amino acid responsible for substrate selectivity of monoamine
RT   oxidase A and B.";
RL   J. Biol. Chem. 272:14033-14036(1997).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18391214; DOI=10.1073/pnas.0710626105;
RA   Son S.-Y., Ma J., Kondou Y., Yoshimura M., Yamashita E., Tsukihara T.;
RT   "Structure of human monoamine oxidase A at 2.2-A resolution: the control of
RT   opening the entry for substrates/inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5739-5744(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) IN COMPLEX WITH INHIBITOR, SUBUNIT,
RP   COFACTOR, AND SUBCELLULAR LOCATION.
RX   PubMed=15050826; DOI=10.1016/j.jmb.2004.02.032;
RA   Ma J., Yoshimura M., Yamashita E., Nakagawa A., Ito A., Tsukihara T.;
RT   "Structure of rat monoamine oxidase A and its specific recognitions for
RT   substrates and inhibitors.";
RL   J. Mol. Biol. 338:103-114(2004).
CC   -!- FUNCTION: Catalyzes the oxidative deamination of primary and some
CC       secondary amine such as neurotransmitters, with concomitant reduction
CC       of oxygen to hydrogen peroxide and has important functions in the
CC       metabolism of neuroactive and vasoactive amines in the central nervous
CC       system and peripheral tissues (PubMed:18391214, PubMed:9162023).
CC       Preferentially oxidizes serotonin (PubMed:20493079). Also catalyzes the
CC       oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal
CC       that can spontaneously condense to 4-hydroxyquinoline
CC       (PubMed:18391214). {ECO:0000269|PubMed:18391214,
CC       ECO:0000269|PubMed:20493079, ECO:0000269|PubMed:9162023}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a secondary aliphatic amine + H2O + O2 = a primary amine + an
CC         aldehyde + H2O2; Xref=Rhea:RHEA:26414, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:17478,
CC         ChEBI:CHEBI:58855, ChEBI:CHEBI:65296; EC=1.4.3.4;
CC         Evidence={ECO:0000269|PubMed:20493079};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a primary methyl amine + H2O + O2 = an aldehyde + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:16153, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:17478, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:228804; EC=1.4.3.21;
CC         Evidence={ECO:0000269|PubMed:18391214, ECO:0000269|PubMed:20493079,
CC         ECO:0000269|PubMed:9162023};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-adrenaline + H2O + O2 = (R)-3,4-dihydroxymandelaldehyde +
CC         H2O2 + methylamine; Xref=Rhea:RHEA:51168, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:59338,
CC         ChEBI:CHEBI:71406, ChEBI:CHEBI:180943;
CC         Evidence={ECO:0000269|PubMed:20493079};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dopamine + H2O + O2 = 3,4-dihydroxyphenylacetaldehyde + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:27946, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:27978, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:59905; Evidence={ECO:0000269|PubMed:20493079};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O2 + tyramine = (4-hydroxyphenyl)acetaldehyde + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:30591, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:15621, ChEBI:CHEBI:16240, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:327995; Evidence={ECO:0000269|PubMed:20493079,
CC         ECO:0000269|PubMed:9162023};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-noradrenaline + H2O + O2 = (R)-3,4-dihydroxymandelaldehyde
CC         + H2O2 + NH4(+); Xref=Rhea:RHEA:69076, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:72587, ChEBI:CHEBI:180943;
CC         Evidence={ECO:0000269|PubMed:20493079};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O2 + serotonin = (5-hydroxyindol-3-yl)acetaldehyde +
CC         H2O2 + NH4(+); Xref=Rhea:RHEA:69072, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:50157, ChEBI:CHEBI:350546;
CC         Evidence={ECO:0000269|PubMed:20493079, ECO:0000269|PubMed:9162023};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + kynuramine + O2 = 3-(2-aminophenyl)-3-oxopropanal + H2O2
CC         + NH4(+); Xref=Rhea:RHEA:59596, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:28938, ChEBI:CHEBI:180898,
CC         ChEBI:CHEBI:180899; Evidence={ECO:0000269|PubMed:18391214};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:59597;
CC         Evidence={ECO:0000305|PubMed:18391214};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O2 + tryptamine = H2O2 + indole-3-acetaldehyde + NH4(+);
CC         Xref=Rhea:RHEA:59416, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:18086, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:57887; Evidence={ECO:0000269|PubMed:9162023};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-phenylethylamine + H2O + O2 = 2-phenylacetaldehyde + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:25265, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:16424, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:225237; Evidence={ECO:0000269|PubMed:20493079,
CC         ECO:0000269|PubMed:9162023};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:15050826};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=610 uM for (R)-adrenaline {ECO:0000269|PubMed:20493079};
CC         KM=150 uM for dopamine {ECO:0000269|PubMed:20493079};
CC         KM=340 uM for serotonin {ECO:0000269|PubMed:20493079};
CC         KM=582 uM for (R)-noradrenaline {ECO:0000269|PubMed:20493079};
CC         KM=327 uM for 2-phenylethylamine {ECO:0000269|PubMed:20493079};
CC         KM=116 uM for tyramine {ECO:0000269|PubMed:20493079};
CC         KM=0.096 mM for kynuramine (with the detergent-solubilized form)
CC         {ECO:0000269|PubMed:18391214};
CC         KM=0.026 mM for kynuramine (with the membrane-bound form)
CC         {ECO:0000269|PubMed:18391214};
CC         KM=0.31 mM for serotonin {ECO:0000269|PubMed:9162023};
CC         KM=0.40 mM for tyramine {ECO:0000269|PubMed:9162023};
CC         KM=0.23 mM for tryptamine {ECO:0000269|PubMed:20493079};
CC         KM=0.24 mM for 2-phenylethylamine {ECO:0000269|PubMed:20493079};
CC         Vmax=558 pmol/min/mg enzyme toward (R)-adrenaline
CC         {ECO:0000269|PubMed:20493079};
CC         Vmax=889 pmol/min/mg enzyme toward dopamine
CC         {ECO:0000269|PubMed:20493079};
CC         Vmax=997 pmol/min/mg enzyme toward serotonin
CC         {ECO:0000269|PubMed:20493079};
CC         Vmax=1213 pmol/min/mg enzyme toward (R)-noradrenaline
CC         {ECO:0000269|PubMed:20493079};
CC         Vmax=53 pmol/min/mg enzyme toward 2-phenylethylamine
CC         {ECO:0000269|PubMed:20493079};
CC         Vmax=258 pmol/min/mg enzyme toward tyramine
CC         {ECO:0000269|PubMed:20493079};
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer (By similarity).
CC       {ECO:0000250|UniProtKB:P21397}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane
CC       {ECO:0000269|PubMed:15050826}; Single-pass type IV membrane protein
CC       {ECO:0000269|PubMed:15050826}; Cytoplasmic side
CC       {ECO:0000269|PubMed:15050826}.
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Approaching happiness
CC       - Issue 172 of August 2015;
CC       URL="https://web.expasy.org/spotlight/back_issues/172/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D00688; BAA00592.1; -; mRNA.
DR   EMBL; S45812; AAB23355.2; -; mRNA.
DR   PIR; JT0528; JT0528.
DR   PDB; 1O5W; X-ray; 3.20 A; A/B/C/D=1-526.
DR   PDBsum; 1O5W; -.
DR   AlphaFoldDB; P21396; -.
DR   SMR; P21396; -.
DR   IntAct; P21396; 1.
DR   MINT; P21396; -.
DR   STRING; 10116.ENSRNOP00000063784; -.
DR   BindingDB; P21396; -.
DR   ChEMBL; CHEMBL3358; -.
DR   DrugCentral; P21396; -.
DR   iPTMnet; P21396; -.
DR   PhosphoSitePlus; P21396; -.
DR   jPOST; P21396; -.
DR   PaxDb; 10116-ENSRNOP00000063784; -.
DR   UCSC; RGD:61898; rat.
DR   AGR; RGD:61898; -.
DR   RGD; 61898; Maoa.
DR   eggNOG; KOG0029; Eukaryota.
DR   InParanoid; P21396; -.
DR   PhylomeDB; P21396; -.
DR   BioCyc; MetaCyc:MONOMER-14994; -.
DR   BRENDA; 1.4.3.4; 5301.
DR   Reactome; R-RNO-141333; Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB.
DR   Reactome; R-RNO-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-379397; Enzymatic degradation of dopamine by COMT.
DR   Reactome; R-RNO-379398; Enzymatic degradation of Dopamine by monoamine oxidase.
DR   Reactome; R-RNO-379401; Dopamine clearance from the synaptic cleft.
DR   Reactome; R-RNO-380612; Metabolism of serotonin.
DR   SABIO-RK; P21396; -.
DR   EvolutionaryTrace; P21396; -.
DR   PRO; PR:P21396; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0052595; F:aliphatic amine oxidase activity; IEA:RHEA.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IDA:RGD.
DR   GO; GO:0097621; F:monoamine oxidase activity; IDA:UniProtKB.
DR   GO; GO:0008131; F:primary amine oxidase activity; IDA:UniProtKB.
DR   GO; GO:0051378; F:serotonin binding; IDA:RGD.
DR   GO; GO:0042424; P:catecholamine catabolic process; NAS:RGD.
DR   GO; GO:0042420; P:dopamine catabolic process; ISO:RGD.
DR   GO; GO:0042443; P:phenylethylamine metabolic process; IDA:RGD.
DR   GO; GO:0009967; P:positive regulation of signal transduction; ISO:RGD.
DR   GO; GO:0042428; P:serotonin metabolic process; IDA:RGD.
DR   Gene3D; 3.90.660.10; -; 1.
DR   Gene3D; 6.10.250.130; -; 1.
DR   Gene3D; 3.50.50.60; FAD/NAD(P)-binding domain; 1.
DR   Gene3D; 1.10.405.10; Guanine Nucleotide Dissociation Inhibitor, domain 1; 1.
DR   InterPro; IPR002937; Amino_oxidase.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   InterPro; IPR001613; Flavin_amine_oxidase.
DR   InterPro; IPR050703; Flavin_MAO.
DR   PANTHER; PTHR43563; AMINE OXIDASE; 1.
DR   PANTHER; PTHR43563:SF11; AMINE OXIDASE [FLAVIN-CONTAINING] A; 1.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
DR   SUPFAM; SSF54373; FAD-linked reductases, C-terminal domain; 1.
DR   SUPFAM; SSF51905; FAD/NAD(P)-binding domain; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Catecholamine metabolism; FAD; Flavoprotein;
KW   Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   Neurotransmitter degradation; Oxidoreductase; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..526
FT                   /note="Amine oxidase [flavin-containing] A"
FT                   /id="PRO_0000099854"
FT   TOPO_DOM        1..497
FT                   /note="Cytoplasmic"
FT   TRANSMEM        498..518
FT                   /note="Helical; Anchor for type IV membrane protein"
FT   TOPO_DOM        519..526
FT                   /note="Mitochondrial intermembrane"
FT   REGION          520..522
FT                   /note="Interaction with membrane phospholipid headgroups"
FT                   /evidence="ECO:0000250"
FT   SITE            335
FT                   /note="Important for substrate specificity"
FT   SITE            374
FT                   /note="Important for catalytic activity"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P21397"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         406
FT                   /note="S-8alpha-FAD cysteine"
FT   MUTAGEN         208
FT                   /note="F->A: Lower affinity for serotonin and tyramine; no
FT                   change for tryptamine."
FT                   /evidence="ECO:0000269|PubMed:9162023"
FT   MUTAGEN         208
FT                   /note="F->I: Lower affinity for serotonin and tyramine; no
FT                   change for tryptamine."
FT                   /evidence="ECO:0000269|PubMed:9162023"
FT   MUTAGEN         208
FT                   /note="F->V: Lower affinity for serotonin and tyramine; no
FT                   change for tryptamine."
FT                   /evidence="ECO:0000269|PubMed:9162023"
FT   MUTAGEN         208
FT                   /note="F->Y: No change in substrate affinity."
FT                   /evidence="ECO:0000269|PubMed:9162023"
FT   CONFLICT        17..18
FT                   /note="GL -> VV (in Ref. 2; AAB23355)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        361
FT                   /note="Q -> L (in Ref. 2; AAB23355)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        406
FT                   /note="C -> S (in Ref. 2; AAB23355)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        451
FT                   /note="A -> R (in Ref. 2; AAB23355)"
FT                   /evidence="ECO:0000305"
FT   STRAND          13..19
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           23..34
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          39..42
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          44..48
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            58..60
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          63..66
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           75..83
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          88..90
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          94..103
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          105..108
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          110..112
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           118..136
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           143..145
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           149..152
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           157..164
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           168..182
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            186..188
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           191..200
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           203..208
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          210..213
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          216..219
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           225..232
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           235..237
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          238..241
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          244..248
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          250..261
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          263..271
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           275..280
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          281..285
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           289..294
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          303..309
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           316..318
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          320..327
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          334..338
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          348..354
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           355..362
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           366..381
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           384..387
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          390..396
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            397..399
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            401..403
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          405..407
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            413..415
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           416..419
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           420..422
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          428..432
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           435..437
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          439..441
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           445..461
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   TURN            462..464
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   STRAND          479..481
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           490..494
FT                   /evidence="ECO:0007829|PDB:1O5W"
FT   HELIX           498..519
FT                   /evidence="ECO:0007829|PDB:1O5W"
SQ   SEQUENCE   526 AA;  59508 MW;  381AE35D5A73E25B CRC64;
     MTDLEKPNLA GHMFDVGLIG GGISGLAAAK LLSEYKINVL VLEARDRVGG RTYTVRNEHV
     KWVDVGGAYV GPTQNRILRL SKELGIETYK VNVNERLVQY VKGKTYPFRG AFPPVWNPLA
     YLDYNNLWRT MDEMGKEIPV DAPWQARHAQ EWDKMTMKDL IDKICWTKTA REFAYLFVNI
     NVTSEPHEVS ALWFLWYVRQ CGGTARIFSV TNGGQERKFV GGSGQVSEQI MGLLGDKVKL
     SSPVTYIDQT DDNIIVETLN HEHYECKYVI SAIPPILTAK IHFKPELPPE RNQLIQRLPM
     GAVIKCMVYY KEAFWKKKDY CGCMIIEDEE APIAITLDDT KPDGSLPAIM GFILARKADR
     QAKLHKDIRK RKICELYAKV LGSQEALYPV HYEEKNWCEE QYSGGCYTAY FPPGIMTQYG
     RVIRQPVGRI YFAGTETATQ WSGYMEGAVE AGERAAREVL NALGKVAKKD IWVEEPESKD
     VPAIEITHTF LERNLPSVPG LLKITGVSTS VALLCFVLYK IKKLPC
//
